Latus
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Latus - overview
Established
2022
Location
Philadelphia, PA, US
Primary Industry
Biotechnology
About
Based in Philadelphia, US, and founded in 2022 and led by Chief Executive Officer Peter Ghoroghchian, Latus Bio, Inc operates as a provider of therapeutics for CNS disorders. In April 2026, Latus Bio, Inc. raised USD 97 million in series A funding led by 8VC, with participation from DCVC, BioAdvance, Ben Franklin Technology Partners, Modi Ventures, Gaingels and Hatch BioFund Management, Korea Development Bank and Helen’s Pink Sky Foundation. Latus Bio, Inc.
specializes in utilizing adeno-associated virus (AAV) vectors to improve the treatment of central nervous system (CNS) disorders. The company’s technology is designed to accurately deliver therapeutic genes to specific tissues, reducing the risks of immunogenicity and toxicity commonly associated with high-dose administrations. Its program target CNS diseases such as Huntington's Disease (HD) and CLN2, provides patients with one-time gene therapies that offer meaningful reductions in toxicity and improved quality of life. The firm plans to use the funding from May 2024 to accelerate the development of its candidates for CLN2 disease, with first-in-human dosing planned in late 2025.
Current Investors
Ben Franklin Technology Partners, Samsung Venture Investment, DCVC
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare
Website
www.latusbio.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.